Events

AI and ML in Healthcare Virtual Event w/ Jackie Hunter

The opportunities and challenges of applying machine learning to drug discovery

Drug discovery and development is poised to be revitalised by artificial intelligence and machine learning. From improving target identification and validation, to better predicting the properties of molecules, new technologies offer the promise of getting more effective therapeutics to the patients who need them, faster. AI also thrives in fast-moving situations and has been successfully deployed during the coronavirus pandemic to discover existing medicines that can be repurposed to treat the virus.

Yet, moving the needle in this field is challenging, and requires the experts from two seemingly disparate fields, both of which focus on tackling exceptionally complex problems, to work together. Other barriers include access to data, particularly negative data and diverse datasets. In this talk, Professor Jackie Hunter will examine case studies of BenevolentAI’s own work and progress in the field, and discuss the opportunities and unique challenges of building an AI platform for drug discovery.

→ Register here


Jackie Hunter
Board Director of BenevolentAI

Jackie Hunter is a Board Director of BenevolentAI.  Jackie has over thirty years of experience in the bioscience research sector, working across academia and industry including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline. She founded OI Pharma Partners in 2010 to support the life science sector in harnessing the power of open innovation and most recently was Chief Executive of the Biotechnology and Biological Sciences Research Council. She holds a personal chair from St George's Hospital Medical School, which was awarded in recognition of her contribution to bioscience research. In 2010 she was awarded a CBE in the Queen's Birthday Honours list for Services to the Pharmaceutical Industry.


More Posts

You Might Also Like

Video
Data & Digital Innovation for Climate & Health
Joanna Shields, CEO BenevolentAI, joined the Wellcome Trust Panel at the World Economic forum to discuss opportunities for data and digital innovation to impact positively climate and health.
Jan 26, 2023
News
BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis
BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.
Dec 21, 2022
News
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
Blog
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
News
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022